diphtheria, tetanus and pertussis vaccine infant (DTcP infant) / CanSino - LARVOL DELTA

Safety and Immunogenicity of Diphtheria, Tetanus and Pertussis (Acellular, Three Components) Combined Vaccine, Adsorbed after three-dose priming in 2 Months Age Infants: A Randomized, Blinded, Controlled Phase III Clinical Trial in China. (PubMed, Emerg Microbes Infect) - "We evaluated a novel diphtheria, tetanus and pertussis (acellular, three components) combined vaccine, adsorbed (DTcP), China's first genetically engineered three-component pertussis vaccine, administered under two primary schedules (2/3/4 vs. 2/4/6 months) compared to licensed DTaP-IPV-Hib (Pentaxim). DTcP exhibited favorable safety and superior pertussis immunogenicity, particularly with the 2/4/6-month schedule. Its genetically engineered three-component design offers a promising strategy to combat pertussis amid global resurgence."

Journal • P3 data • Infectious Disease • Novel Coronavirus Disease • Pertussis • Respiratory Diseases • Tetanus

Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine (clinicaltrials.gov) - P1 | N=260 | Recruiting | Sponsor: CanSino Biologics Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Infectious Disease • Influenza • Meningococcal Infections • Pertussis • Respiratory Diseases • Tetanus

Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine (clinicaltrials.gov) - P1 | N=260 | Not yet recruiting | Sponsor: CanSino Biologics Inc.

New P1 trial • CNS Disorders • Infectious Disease • Influenza • Meningococcal Infections • Pertussis • Respiratory Diseases • Tetanus

Inter-lot Consistency Clinical Trial of Adsorbed Cell-free DTP (Three-component) Combined Vaccine (clinicaltrials.gov) - P3 | N=780 | Active, not recruiting | Sponsor: CanSino Biologics Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Pertussis • Respiratory Diseases • Tetanus

Inter-lot Consistency Clinical Trial of Adsorbed Cell-free DTP (Three-component) Combined Vaccine (clinicaltrials.gov) - P3 | N=780 | Recruiting | Sponsor: CanSino Biologics Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pertussis • Respiratory Diseases • Tetanus

A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP) (clinicaltrials.gov) - P3 | N=2520 | Active, not recruiting | Sponsor: CanSino Biologics Inc. | Trial completion date: Aug 2024 ➔ Apr 2025 | Trial primary completion date: Aug 2024 ➔ Apr 2025

Trial completion date • Trial primary completion date • Infectious Disease • Pertussis • Respiratory Diseases • Tetanus

Inter-lot Consistency Clinical Trial of Adsorbed Cell-free DTP (Three-component) Combined Vaccine (clinicaltrials.gov) - P3 | N=780 | Not yet recruiting | Sponsor: CanSino Biologics Inc.

New P3 trial • Infectious Disease • Pertussis • Respiratory Diseases • Tetanus

A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP) (clinicaltrials.gov) - P3 | N=2520 | Active, not recruiting | Sponsor: CanSino Biologics Inc. | Recruiting ➔ Active, not recruiting | Trial primary completion date: Feb 2024 ➔ Aug 2024

Enrollment closed • Trial primary completion date • Infectious Disease • Pertussis • Respiratory Diseases • Tetanus

A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP) (clinicaltrials.gov) - P3 | N=2520 | Recruiting | Sponsor: CanSino Biologics Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pertussis • Respiratory Diseases • Tetanus

A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP) (clinicaltrials.gov) - P3 | N=2520 | Not yet recruiting | Sponsor: CanSino Biologics Inc.

New P3 trial • Infectious Disease • Pertussis • Respiratory Diseases • Tetanus

PICTDTOV: Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed . (clinicaltrials.gov) - P1 | N=400 | Completed | Sponsor: CanSino Biologics Inc. | Unknown status ➔ Completed

Trial completion • Infectious Disease • Pertussis • Respiratory Diseases • Tetanus